United States · FDA National Drug Code directory
EVEROLIMUS
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 70377-012_4e63b36e-3d75-b3b0-42b6-f2f3c1ddf4d0
- Product NDC
- 70377-012
- Form
- TABLET
- Composition / generic term
- everolimus
- Labeler
- Biocon Pharma Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20211001
- Source listing expiry
- 20261231
Source-listed ingredients
- EVEROLIMUS — 7.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET in 1 BOTTLE (70377-012-11) · 70377-012-11
- 4 BLISTER PACK in 1 CARTON (70377-012-22) / 7 TABLET in 1 BLISTER PACK · 70377-012-22
- 4 BLISTER PACK in 1 CARTON (70377-012-23) / 7 TABLET in 1 BLISTER PACK · 70377-012-23
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →